Jaguar Health (JAGX) files DEF 14A seeking shareholder approval for massive dilution: Series Q Preferred conversion…
Key takeaway
Jaguar Health (JAGX) files DEF 14A seeking shareholder approval for massive dilution: Series Q Preferred conversion, warrant repricing from $525+ to $1.00, reverse stock split, and ELOC floor price collapse from $16.50 to $1.10
- Step 1 · The triggerJaguar Health files DEF 14A seeking approval for massive dilution via Series Q Preferred conversion, warrant repricing to $1.00, reverse split, and ELOC floor collapse to $1.10
- Step 2 · Knock-onChicago Venture Partners and C/M Capital capture value through preferential conversion terms while common shareholders face severe economic dilution
- Step 3 · Knock-onthe reverse split and floor-price reduction signal imminent Nasdaq bid-price deficiency, accelerating compliance-driven financial engineering
- Step 4 · Reaches youUS SMEs with PIPE or convertible exposure in their portfolios or advisory roles face impaired equity and must reprice counterparty risk
The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.
Source: SEC EDGAR — Current filings
See what today’s news does to your business. Atri by Branch² — Early-warning intelligence for your businessThis is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.